Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

SL-010110 inhibits gluconeogenesis and improves glucose homeostasis in diabetic mice

Dec. 23, 2021

Alnylam submits CTA in U.K. for ALN-XDH to treat gout

Dec. 22, 2021

Discovery of T-036, a novel brain-penetrant GCS inhibitor for the treatment of Gaucher's disease

Dec. 20, 2021

Design of novel SSTR2 agonists for acromegaly

Dec. 17, 2021

First preclinical data presented for chimeric fusion protein AT-03 in amyloidosis

Dec. 17, 2021

Shanghai Institutes for Biological Sciences presents islet-like cell clusters

Dec. 10, 2021

New model for studying early embryonic development

Dec. 9, 2021

RAGE-229 inhibits RAGE-DIAPH1 binding and lessens diabetic complications in mice

Dec. 2, 2021

Shanghai Zheye Biotechnology divulges new SGLT-1 inhibitors

Dec. 2, 2021

IL-27 drives metabolic programs and its targeting aids in the treatment of obesity

Dec. 2, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...